Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.69 |
| ▸ | CDK8 | P49336 | 14/20 | 0.69 |
| ▸ | AXL | P30530 | 2/20 | 0.69 |
| ▸ | CDK7 | P50613 | 2/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.66 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.66 |
| ▸ | CDK1 | P06493 | 2/20 | 0.66 |
| ▸ | FES | P07332 | 2/20 | 0.66 |
| ▸ | ROS1 | P08922 | 2/20 | 0.66 |
| ▸ | FER | P16591 | 2/20 | 0.66 |
| ▸ | FLT4 | P35916 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.66 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.66 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.66 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.66 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.66 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064962 | 1.00 | RIPK1 (0.69) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL4831501 | 0.83 | CDK8 (0.81) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL3136284 | 0.83 | CDK8 (0.71) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL22978455 | 0.82 | RIPK1 (1.00) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL410704 | 0.82 | CDK8 (1.00) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL857125 | 0.81 | CDK8 (0.69) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL857038 | 0.81 | CDK8 (0.69) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL857974 | 0.81 | CDK8 (1.00) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL857070 | 0.80 | CDK8 (1.00) | RIPK1CDK8AXLCDK7MAP4K4 | |
| SCHEMBL30368585 | 0.80 | CDK8 (1.00) | RIPK1CDK8AXLCDK7MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | GlaxoSmithKline, LLC | 2012-09-20 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | GLAXOSMITHKLINE LLC | 2009-09-17 | — | — | US | disclosed |
| WO-2006063167-A1 | 1H-PYRROLO[2,3-B]PYRIDINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233955-A1 | 1H-Pyrrolo[2,3-B]Pyridnes | SGK1, SGK2, SGK3 | RIPK1 143/4885CDK8 525/4885AXL 1542/4885 |
| US-20120238588-A1 | 1H-Pyrrolo[2,3-B]Pyridines | SGK1, SGK2, SGK3 | RIPK1 161/4885CDK8 639/4885AXL 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.